What is claimed:

1. A pharmaceutical composition useful in treating multiple sclerosis in mammals, which composition comprises a pharmaceutically acceptable excipient and a therapeutically effective amount of a human IFN-β2 polypeptide, a biologically-active fragment thereof, or a biologically-active derivative thereof.

2. The pharmaceutical composition of Claim 1 wherein the mammal in need thereof is a human.

3. A method of administering to a mammal in need thereof a pharmaceutical composition useful in multiple sclerosis in mammals, which composition comprises a pharmaceutically acceptable excipient and a therapeutically effective amount of a human IFN-β2 polypeptide, a biologically-active fragment thereof, or a biologically-active derivative thereof.

4. The method of Claim 3 wherein the mammal in need thereof is a human.